decemb
new
type
pneumonia
support
novel
member
coronovirida
famili
name
sever
acut
respiratori
coronaviru
syndrom
develop
wuhan
provinc
china
phylogenet
analysi
demonstr
differ
viru
nucleotid
ident
diseas
caus
character
dri
cough
fever
dyspnea
fatigu
accompani
lymphopenia
sever
case
appar
infect
patient
pictur
may
becom
complic
onset
interstiti
pneumonia
alveolar
damag
clinic
lead
sever
acut
respiratori
distress
syndrom
ard
even
death
sinc
initi
outbreak
epidem
rapid
global
spread
worldwid
led
world
health
organ
declar
diseas
call
public
health
emerg
intern
concern
januari
pandem
march
epidemiolog
pictur
constantli
evolv
data
updat
march
count
countri
involv
case
confirm
death
context
grow
health
emerg
clarifi
relationship
popul
fragil
patient
suffer
immunerheumatolog
diseas
absolut
crucial
one
hand
rapid
uncontrol
spread
epidem
clearli
gener
even
concern
rheumat
patient
intrins
character
increas
infecti
risk
due
diseas
iatrogen
effect
immunosuppress
agent
corticosteroid
synthet
biolog
diseasemodifi
drug
hand
grow
knowledg
pathogenesi
infect
lead
introduct
drug
commonli
use
treatment
rheumatoid
arthriti
ra
even
manag
complex
case
chloroquin
hydroxychloroquin
perman
includ
alongsid
antivir
drug
protocol
treatment
pneumonia
addit
use
interleukin
blocker
seem
promis
manag
massiv
cytokin
storm
associ
develop
typic
lung
damag
consequ
ard
occur
aggress
pattern
sarscov
infect
therefor
wait
observ
data
incid
rheumatolog
patient
best
strategi
manag
immunerheumatolog
diseas
emerg
period
still
far
clear
purpos
review
provid
overview
viral
infecti
risk
ra
patient
particular
focu
http
receiv
march
accept
march
knowledg
current
new
pandem
use
antirheumat
drug
context
health
emerg
coronavirus
largest
virus
positivesens
singlestrandedrna
genom
host
immun
respons
one
side
essenti
resolut
infect
also
crucial
pathogenesi
major
clinic
manifest
diseas
angiotensinconvert
enzym
identifi
host
cellsurfac
receptor
envelop
spike
glycoprotein
type
membran
protein
express
cell
kidney
heart
gastrointestin
tract
blood
vessel
importantli
lung
alveolar
epitheli
cell
particularli
prone
viral
infect
infect
lead
downregul
express
thu
result
excess
product
angiotensin
ii
relat
enzym
ace
suggest
stimul
type
angiotensin
ii
receptor
increas
pulmonari
vascular
permeabl
thu
potenti
explain
increas
lung
damag
express
decreas
due
mechan
action
postul
subject
diabet
mellitu
hypertens
use
aceinhibitor
angiotensin
receptor
blocker
may
increas
risk
infect
sever
scarc
evid
support
hypothesi
european
societi
cardiolog
recent
publish
posit
statement
strongli
recommend
continu
treatment
despit
current
epidem
addit
point
clarifi
also
role
genet
predisposit
increas
risk
infect
due
polymorph
link
hypertens
diabet
mellitu
cerebr
stroke
especi
asian
popul
viral
rna
genom
releas
cytoplasm
rna
uncoat
allow
translat
two
polyprotein
transcript
subgenom
rna
replic
viral
genom
progress
ard
associ
upregul
proinflammatori
cytokin
chemokin
known
cytokin
releas
syndrom
cr
pattern
similar
secondari
haemophagocyt
lymphohistiocytosi
shlh
adult
shlh
underrecogn
hyperinflammatori
syndrom
character
massiv
fatal
hypercytokinaemia
multiorgan
failur
commonli
trigger
viral
infect
main
clinic
featur
shlh
includ
unremit
fever
hyperferritinaemia
cytopenia
pulmonari
involv
includ
ard
occur
approxim
patient
cytokin
profil
resembl
shlh
report
sever
infect
character
increas
level
number
cytokin
tumor
necrosi
tnf
chemokin
cxcchemokin
ligand
ccchemokin
ligand
manag
cytokin
storm
one
major
unmet
need
regard
infect
relationship
ra
infecti
diseas
complex
interpret
two
differ
direct
one
hand
fact
potenti
role
extern
microorgan
produc
acut
chronic
arthriti
form
either
direct
colon
joint
pathogen
aberr
autoimmun
reaction
produc
host
respons
infect
well
known
studi
investig
potenti
link
respiratori
viral
infect
develop
ra
particular
korean
studi
report
parainfluenza
coronaviru
associ
number
incid
ra
addit
patient
overt
inflammatori
arthriti
infect
major
concern
contribut
diseas
flare
hand
ra
patient
carri
document
increas
risk
infect
compar
gener
popul
populationbas
studi
doran
colleagu
compar
two
match
group
patient
without
ra
show
ra
patient
significantli
higher
risk
seriou
rr
ci
hospit
rr
ci
infect
similarli
prospect
cohort
studi
conduct
patient
inflammatori
polyarthr
report
increas
risk
hospit
infect
compar
healthi
popul
trend
primarili
result
gener
impair
immun
system
typic
autoimmun
disord
strictli
depend
degre
diseas
activ
fact
demonstr
analysi
conduct
ra
patient
us
corrona
registri
unit
increas
diseas
activ
score
correspond
increas
rate
infect
requir
hospit
incid
rate
ratio
irr
p
increas
rate
outpati
infect
irr
p
addit
subsequ
report
registri
show
risk
seriou
infect
increas
progress
patient
achiev
clinic
remiss
achiev
low
adjust
irr
ci
moder
adjust
irr
ci
diseas
activ
demonstr
import
maintain
good
diseas
control
order
reduc
infecti
complic
anoth
import
determin
infecti
risk
presenc
comorbid
often
complic
cours
ra
diabet
mellitu
cardiovascular
diseas
renal
failur
interstiti
lung
diseas
chronic
obstruct
pulmonari
diseas
copd
concomit
disord
associ
increas
incid
infect
ra
final
ra
also
complic
infect
caus
iatrogen
effect
immunosuppress
therapi
discuss
detail
next
section
year
corticosteroid
cs
pivot
ra
manag
role
remiss
induc
bridg
therapi
manag
diseas
flare
recent
renew
latest
updat
eular
recommend
ra
treatment
even
though
cs
efficaci
rapidli
suppress
inflamm
ra
initi
cours
flare
well
recogn
downsid
broad
spectrum
advers
event
includ
sever
infect
high
risk
develop
comorbid
increas
risk
infect
although
rct
conduct
past
cs
show
higher
risk
infect
ra
patient
cohort
casecontrol
studi
report
increas
rate
overal
infect
ra
patient
treat
cs
accord
dosedepend
fashion
major
infecti
event
bacteri
etiolog
ra
patient
receiv
cs
exhibit
greater
risk
develop
even
viral
infect
exampl
retrospect
cohortstudi
demonstr
increas
risk
herp
zoster
infect
incid
rate
case
per
patientyear
cs
treat
popul
thu
cs
one
hand
inhibit
immun
respons
delay
clearanc
pathogen
hand
suppress
host
inflammatori
respons
case
viral
infect
respiratori
tract
major
respons
lung
damag
occurr
ard
latter
repres
ration
wide
use
cs
manag
middl
east
respiratori
syndrom
mer
cov
sarscov
outbreak
histolog
character
lung
inflamm
diffus
alveolar
damag
howev
evid
literatur
point
predominantli
neg
effect
cs
manag
type
infect
systemat
review
metaanalysi
includ
ten
observ
studi
n
conduct
influenza
report
increas
mortal
risk
ratio
rr
ci
p
increas
rate
secondari
bacteri
fungal
infect
rr
ci
p
longer
stay
intens
care
unit
mean
differ
ci
p
patient
receiv
cs
moreov
review
explor
treatment
ard
includ
six
studi
total
patient
conclud
insuffici
evid
exist
recommend
cs
treatment
overal
clear
reason
exist
expect
patient
infect
benefit
cs
might
like
harm
therapi
fact
current
interim
guidanc
clinic
manag
infect
advis
use
cs
unless
indic
anoth
reason
role
nsaid
cours
viral
infect
still
controversi
ibuprofen
demonstr
induc
overexpress
use
diabet
rat
effect
might
theoret
increas
suscept
worsen
clinic
cours
infect
treat
patient
addit
use
nsaid
acetaminophen
could
associ
mask
fever
rise
result
delay
diagnosi
proper
manag
infect
comprehens
analysi
infecti
risk
patient
treat
csdmard
retrospect
longitudin
studi
populationbas
ra
cohort
use
administr
databas
includ
total
individu
ra
provid
personyear
followup
use
csdmard
without
corticosteroid
associ
small
decreas
mild
infect
risk
recent
systemat
review
metaanalysi
literatur
confirm
lack
increas
risk
infect
patient
receiv
mtx
rr
ci
howev
report
provid
data
risk
stratifi
infect
pathogen
risk
infect
observ
ra
patient
treat
bdmard
gener
consid
slightli
higher
compar
csdmard
evid
recur
rct
observ
registri
studi
confirm
recent
metaanalysi
show
risk
progress
increas
relat
use
bdmard
higher
recommend
dosag
follow
result
compar
metanalys
reallif
studi
abatacept
accept
safest
bdmard
term
infecti
risk
data
focus
viral
respiratori
infect
bdmard
cohort
still
limit
incid
influenzalik
infect
observ
cohort
italian
patient
treat
bdmard
influenza
season
higher
valu
report
wide
sampl
italian
popul
period
even
though
import
complic
hospit
report
overal
postmarket
experi
rel
reassur
antitnf
treat
patient
may
specif
increas
risk
influenza
sever
advers
outcom
includ
death
appear
exceedingli
frequent
overal
risk
seriou
opportunist
infect
observ
janu
kinas
jak
inhibitor
ra
patient
roughli
compar
bdmard
although
earli
year
tofacitinib
baricitinib
use
rais
issu
increas
risk
herp
zoster
viru
hzv
infect
data
tofacitinib
pool
popul
enrol
rct
show
hzv
incid
rate
per
patientyear
greater
incid
geograph
area
high
hzv
endem
doubl
rate
ra
patient
receiv
jaki
similar
pictur
also
observ
overal
develop
program
baricitinib
incid
rate
case
per
patientyear
subsequ
reallif
experi
us
claim
databas
reveal
risk
hzv
higher
patient
receiv
tofacitinib
compar
treat
abatacept
ahr
ci
risk
seriou
hospit
hzv
infect
higher
versu
bdmard
older
age
femal
sex
prednison
mgday
prior
infect
greater
number
hospit
associ
increas
hzv
risk
wherea
vaccin
associ
lower
risk
recent
report
rct
conduct
novel
select
inhibitor
upadacitinib
filgotinib
basic
confirm
trend
suggest
increas
hzv
infect
consid
class
effect
jaki
although
exact
mechan
hzv
reactiv
occur
context
jak
inhibit
unclear
downregul
cellmedi
immun
innat
antivir
signal
type
ii
interferon
ifn
like
involv
current
data
avail
risk
respiratori
viru
infect
carri
jak
inhibitor
current
vaccin
approv
target
therapeut
treatment
new
infect
still
lack
manag
support
even
though
multitud
compound
investig
treatment
emerg
diseas
need
urgent
identifi
effect
approach
manag
led
strategi
test
efficaci
exist
antivir
drug
commonli
use
viral
infect
particular
consid
similar
betacoronaviru
associ
previou
epidem
sarscov
merscov
drug
use
controversi
result
condit
interferon
ribavirin
lopinavirritonavir
consid
even
anecdot
case
demonstr
abil
lopinavirritonavir
significantli
reduc
viral
load
improv
diseas
outcom
addit
remdesivir
adenosin
analogu
current
develop
manag
ebola
viru
infect
recent
recogn
promis
antivir
therapi
wide
spectrum
rna
virus
show
good
preliminari
vitro
result
control
infect
consequ
lopinavirritonavir
remdesevir
current
antivir
drug
includ
sever
case
manag
protocol
recent
report
describ
potenti
role
human
monoclon
antibodi
bind
coronaviru
spike
receptor
bind
domain
lead
neutral
capabl
interact
human
target
cell
howev
moment
consid
potenti
treatment
option
futur
obvious
avail
manag
current
pandem
beyond
use
specif
antivir
product
mani
drug
commonli
use
treatment
ra
propos
possibl
therapi
consequ
increas
knowledg
pathophysiolog
infect
tabl
chloroquin
hydroxychloroquin
wide
use
antimalari
drug
wellknown
immunomodulatori
properti
extend
use
sever
immunorheumatolog
diseas
includ
ra
abil
chloroquin
produc
antivir
effect
known
sinc
late
sever
mechan
drug
abl
interfer
growth
spread
differ
virus
includ
sar
coronaviru
demonstr
vitro
studi
even
though
subsequ
vivo
experi
controversi
clinic
admiss
concentr
chloroquin
abl
increas
endosom
ph
requir
viruscel
fusion
inhibit
tolllik
receptor
activ
interfer
termin
glycosyl
cellular
receptor
ace
function
may
neg
influenc
virusreceptor
bind
result
potenti
effect
drug
entri
postentri
stage
sar
cov
infect
consequ
chloroquin
recent
includ
least
random
control
trial
current
ongo
china
test
treatment
variou
combin
protocol
antivir
drug
mention
interim
result
patient
demonstr
chloroquin
superior
control
treatment
improv
lung
imag
find
inhibit
exacerb
pneumonia
promot
viru
neg
convers
shorten
diseas
cours
differ
level
sever
recent
hydroxychloroquin
demonstr
potent
chloroquin
vitro
studi
base
pharmacokinet
model
pbpk
oral
load
dose
mg
twice
daili
follow
mainten
dose
mg
given
twice
daili
day
seem
best
option
manag
infect
alreadi
describ
ard
occur
sever
case
infect
mainli
produc
massiv
releas
proinflammatori
mediat
cr
associ
viral
replic
lung
injuri
lead
multiorgan
failur
moreov
high
level
cytokin
report
invers
relat
absolut
lymphocyt
count
surviv
tcell
function
exhaust
sinc
effect
immun
respons
viral
infect
depend
activ
cytotox
cell
cr
might
associ
decreas
viral
clearanc
contribut
worsen
play
pivot
role
hyperinflammatori
condit
suggest
potenti
use
blocker
treatment
option
relat
interstiti
pneumonia
data
phase
rct
blockad
anakinra
sepsi
show
signific
surviv
benefit
patient
hyperinflamm
without
increas
advers
event
small
retrospect
studi
patient
affect
sever
demonstr
tocilizumab
improv
ct
scan
abnorm
oxygen
satur
normal
crp
level
lymphocyt
count
patient
multicentr
rct
tocilizumab
receptor
blocker
licens
ra
cytokin
releas
syndrom
approv
china
current
ongo
patient
pneumonia
elev
level
phase
ii
studi
approv
italian
regulatori
drug
agenc
aifa
enrol
patient
pneumonia
earli
respiratori
failur
mortal
reduct
primari
outcom
moreov
compani
produc
second
market
inhibitor
sarilumab
recent
announc
intent
undertak
studi
similar
design
identif
uniqu
definit
cr
infect
crucial
better
custom
manag
critic
patient
presenc
larg
area
lung
injuri
decreas
level
tlymphocyt
lower
minimum
normal
rang
increas
level
peripher
blood
recogn
greatest
risk
factor
cr
retrospect
analysi
critic
pneumonia
chines
patient
infect
increas
ferritin
level
erythrocyt
sediment
rate
decreas
platelet
count
would
addit
paramet
potenti
use
discrimin
patient
requir
immunosuppress
treatment
previous
describ
sarscov
infect
associ
downregul
express
coupl
increas
activ
reninangiotensin
system
respons
lung
injuri
moreov
viral
spike
protein
abl
induc
enzym
tace
depend
shed
ectodomain
crucial
penetr
viru
cell
sinc
process
seem
strictli
coupl
product
postul
use
tnf
inhibitor
may
effect
reduc
infect
consequ
organ
damag
result
studi
evalu
adalimumab
infect
recent
regist
chines
clinic
trial
registri
previous
describ
detail
enter
target
cell
receptormedi
endocytosi
identifi
regul
clathrinmedi
endocytosi
member
numbassoci
kinas
nak
famili
protein
kinas
cyclin
gassoci
kinas
gak
inhibit
may
stop
access
viru
lung
cell
also
intracellular
assembl
viru
particl
blocker
approv
unfortun
compound
abl
produc
adequ
nak
inhibit
dose
significantli
higher
normal
use
clinic
practic
therefor
potenti
toxic
patient
convers
jak
inhibitor
baricitinib
abl
effect
inhibit
gak
plasma
concentr
obtain
approv
dosag
treatment
ra
mg
daili
moreov
select
inhibitor
jak
baricitinib
also
abl
produc
import
dampen
host
inflammatori
respons
due
cr
includ
interferon
gamma
respons
sever
form
interstiti
pneumonia
final
minim
interact
baricitinib
relev
cyp
drugmetabolis
enzym
make
drug
possibl
candid
inclus
combin
protocol
antivir
drug
lopinavirritonavir
remdesivir
interestingli
tofacitinib
show
detect
inhibit
wherea
current
data
avail
possibl
effect
jak
inhibitor
approv
test
ra
upadacitinib
filgotinib
relat
coronaviru
infect
unexpectedli
clinic
trial
evalu
potenti
role
clathrinmedi
endocytosi
blockad
manag
current
ongo
ruxolitinib
side
ifn
one
potent
innat
immun
respons
prevent
viral
replic
earli
phase
infect
activ
transcript
jakstat
signal
pathway
ifn
lead
upregul
sever
interferon
stimul
gene
abil
rapidli
kill
virus
within
infect
cell
almost
virus
develop
strategi
combat
effect
type
type
ifn
block
ifn
signal
pathway
viral
encod
factor
abl
antagon
jakstat
pathway
crucial
determin
virul
particular
influenza
virus
disrupt
jakstat
signal
reduc
express
ifn
receptor
directli
inhibit
ifn
signal
consequ
jakstat
blockad
gener
baricitinib
certainli
produc
impair
ifnmedi
antivir
respons
potenti
facilit
effect
progress
infect
moment
yet
better
quantifi
conclus
evid
possibl
use
baricitinib
treatment
infect
remain
highli
controversi
studi
warrant
better
clarifi
potenti
role
treatment
seriou
case
viral
pneumonia
epidem
repres
health
emerg
inevit
affect
manag
complex
diseas
ra
chronic
autoimmun
inflammatori
disord
ra
carri
higher
infecti
risk
gener
popul
use
synthet
biolog
diseasemodifi
drug
associ
potenti
increas
incid
seriou
infect
poor
control
ra
diseas
activ
even
greater
infecti
risk
factor
thu
ra
patient
encourag
continu
treatment
even
outbreak
opinion
strategi
reason
aim
prevent
diseas
flare
contribut
increas
patient
burden
disabl
poor
qualiti
life
healthcar
use
addit
discontinu
ongo
treatment
could
lead
need
introduc
cs
bridg
therapi
may
increas
risk
viral
infect
well
inappropri
manag
interstiti
pneumonia
chloroquin
hydroxychloroquin
current
includ
treatment
protocol
manag
infect
might
use
prevent
mitig
cours
infect
patient
ra
take
csdmard
use
inhibitor
tocilizumab
sarilumab
seem
promis
manag
critic
case
interstiti
pneumonia
complic
cr
identif
definit
criteria
discrimin
patient
treat
compound
still
debat
final
although
baricitinib
potenti
affect
penetr
pulmonari
epitheli
cell
major
concern
remain
inhibit
ifn
activ
could
detriment
cours
viral
infect
